Skip to content

Septerna, Inc. SEPN Return on assets

Return on assets at other companies

Amgen logo
AmgenAMGN
8.6%+2.1pp
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
-39.9%-56.4pp
Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
-47.2%+2.5pp
Rapport Therapeutics, Inc. logo
Rapport Therapeutics, Inc.RAPP
-26.8%
Maze Therapeutics, Inc. Common Stock logo
Maze Therapeutics, Inc. Common StockMAZE
-32.6%
Fortrea Holdings Inc. logo
Fortrea Holdings Inc.FTRE
-15.4%-3.4pp

Other financials

Income statement

See full
Revenue$26.5M+12,011%
Operating income-$13.3M+48.7%
Net income-$8.6M+59.8%
EPS (diluted)-$0.19+61.2%

Balance sheet

See full
Cash & equivalents$71.6M-65.9%
Total debt$23.1M-7.7%
Total equity$378.5M+195%
Total assets$569.7M+31.3%

Cash flow

See full
Operating cash flow-$25.6M-9.8%
CapEx$832.0K+118%
Free cash flow-$26.5M-11.5%

Valuation

See full
Market cap$1.62B+319%

Profitability

See full
Operating margin-77.1%-38.4pp
Net margin-49.9%-24.9pp
FCF margin467.9%+243pp

Returns & leverage

See full
Return on equity-12.2%
Debt / equity0.1×
Current ratio4.7×-27.5×

Where this comes from

Calculated from Septerna, Inc.’s reported figures.

Based on trailing twelve months.

The official record: Septerna, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Septerna, Inc.'s return on assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Septerna, Inc.'s return on assets?
Septerna, Inc. (SEPN) reported return on assets of -7.2% in Q1 2026.
What does return on assets mean?
Trailing-twelve-month net income divided by average total assets. Measures how efficiently the asset base generates profit, independent of how those assets are financed. Computed as net income over average total assets — note this is OpenCapital's standard definition and may differ from data vendors that use alternative numerators.